Abstract Aim of the study: Patients with cancer might have an increased risk for severe outcome of coronavirus disease 2019 (COVID-19). To identify risk factors associated with a worse outcome of COVID-19, a nationwide registry was developed for patients with cancer and COVID-19. Methods: This observational cohort study has been designed as a quality of care registry and is executed by the Dutch Oncology COVID-19 Consortium (DOCC), a nationwide collaboration of oncology physicians in the Netherlands. A questionnaire has been developed to collect pseudonymised patient data on patients’ characteristics, cancer diagnosis and treatment. All patients with COVID-19 and a cancer diagnosis or treatment in the past 5 years are eligible. Results: Between March 27th and May 4th, 442 patients were registered. For this first analysis, 351 patients were included of whom 114 patients died. In multivariable analyses, age 65 years (p < 0.001), male gender (p Z 0.035), prior or other malignancy (p Z 0.045) and active diagnosis of haematological malignancy (p Z 0.046) or lung cancer (p Z 0.003) were independent risk factors for a fatal outcome of COVID-19. In a subgroup analysis of patients with active malignancy, the risk for a fatal outcome was mainly determined by tumour type (haematological malignancy or lung cancer) and age (65 years). Conclusion: The findings in this registry indicate that patients with a haematological malignancy or lung cancer have an increased risk of a worse outcome of COVID-19. During the ongoing COVID-19 pandemic, these vulnerable patients should avoid exposure to severe acute respiratory syndrome coronavirus 2, whereas treatment adjustments and prioritising vaccination, when available, should also be considered

, , , ,
doi.org/10.1016/j.ejca.2020.09.027, hdl.handle.net/1765/133630
European Journal of Cancer
Department of Pulmonology

de Joode, K., Dumoulin, D.W., Tol, J., Westgeest, H.M, Beerepoot, L.V, van den Berkmortel, F.W.P., … Bootsma, G.P. (2020). Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study. European Journal of Cancer, 141, 171–184. doi:10.1016/j.ejca.2020.09.027